ClinicalTrials.gg
CompletedNCT03383653Updated Mar 6, 2018

Safety Profile Following Td Vaccination in Indonesian Pregnant Woman

An observational study in Healthy and Pregnant, sponsored by PT Bio Farma. Completed at 1 site in Indonesia. Open to female participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-06.

Sponsored by PT Bio Farma · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 39 Years
Sex
Female
01

Study summary

To assess any serious systemic reaction within 30 minutes after Td immunization in pregnant woman

Read the detailed description

Any local and systemic reaction after Td immunization in pregnant woman (as a routine immunization program)

02

Conditions studied

  • Healthy
  • Pregnant

Keywords

  • Td Vaccine
  • Safety
  • Pregnant
  • Pregnant Women
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

200 pregnant woman, 18-39 years old From provincial health primary center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Pregnant Woman aged 18-39 years old
  • 27-36 weeks of pregnancy
  • Subject have been informed properly regarding the study and signed the form
  • Subject will commit to comply with the instructions of the investigator and the schedule of the trial

Exclusion criteria

Exclusion Criteria:

  • Given simultaneously with other vaccines or with the interval less than 1 month with other vaccination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Target follow-up
1 Month
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Any serious adverse event occurring from inclusion until 30 minutes after the injection

    local and systemic reaction

    Time frame: 30 minutes

Secondary outcomes

  1. Percentage of local and systemic events occurring within 72 hours after each injection

    any local and systemics events

    Time frame: 72 hours

  2. Percentage of local and systemic events occurring from 72 hours up to 28 days following injection.

    any local and systemics events

    Time frame: 72 hours - 28 days

  3. Percentage of serious adverse events within 28 days after injection

    Any serious adverse events

    Time frame: 28 days

07

Study locations

1 site
  • Jakarta Provincial Ministry of Health
    Jakarta, Jakarta Province, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jan 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2017
First posted
Dec 26, 2017
StartActual
Aug 29, 2017
Primary completionActual
Jan 15, 2018
CompletionActual
Jan 31, 2018
Last update
Mar 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03383653
Lead sponsor
PT Bio Farma
Collaborators
Indonesian Vaccine Safety Advisory Committee
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Aug 29, 2017
Primary completion
Jan 15, 2018
Completion
Jan 31, 2018
Last update
Mar 6, 2018

Study contacts

Julitasari Sundoro, MD
principal investigator · Indonesian Vaccine Safety Advisory Commitee

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion